// App-Quantinova.ai

SAT0225 (2018) : Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC

Researchers

Presenter

  • B. Fautrel

Principal Investigators

  • B. Zhu

  • P. C. Taylor

  • M. van de Laar

  • P. Emery

  • F. De Leonardis

  • C. Gaich

  • C. Nicolay

  • Z. Kadziola

  • I. De La Torre

  • R. Fleischmann

Medical Centers

  • Universite Pierre et Marie Curie Paris VI, Paris, France

  • Eli Lilly and Company Indianapolis IN United States

  • Botnar Research Center, Univ. of Oxford, Oxford, United Kingdom

  • Arthritis Centre Twente, Enschede, Netherlands

  • Leeds MSK Biomed/Chapel Allerton Hosp, Leeds, United Kingdom

  • U of Texas Southwestern Med Center, Dallas, United States

Locations

  • France

  • United States

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Tocilizumab

  • Baricitinib

  • Tasocitinib

  • Adalimumab

  • BARI

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved